AU2019204432A1 - Salve formulation - Google Patents

Salve formulation Download PDF

Info

Publication number
AU2019204432A1
AU2019204432A1 AU2019204432A AU2019204432A AU2019204432A1 AU 2019204432 A1 AU2019204432 A1 AU 2019204432A1 AU 2019204432 A AU2019204432 A AU 2019204432A AU 2019204432 A AU2019204432 A AU 2019204432A AU 2019204432 A1 AU2019204432 A1 AU 2019204432A1
Authority
AU
Australia
Prior art keywords
formulation
leaf
approximately
extractant
pittosporum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019204432A
Inventor
Brenda Jamnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2019204432A priority Critical patent/AU2019204432A1/en
Publication of AU2019204432A1 publication Critical patent/AU2019204432A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

A salve formulation is disclosed which can be effective in the treatment of cancer, abrasions, burns, psoriasis, eczema and other skin disorders. Pittosporum angustifolium leaf is placed in a dark environment until dried. Once dried, the leaf is ground to a powder. Backhousia citriodora leaf is immersed in sunflower oil and placed in a dark environment until the leaf is translucent. Bees wax is heated until partially liquified. The mixture of Backhousia citriodora leaf and sunflower oil is added to the heated bees wax and stirred to evenly combine to form an emulsion. Once the emulsion has formed, the dried Pittosporum angustifolium leaf is added and stirred to evenly distribute therethrough. The resultant mixture is filtered and the resultant filtrate (the required formulation) isolated and placed into a suitable storage vessel until required for use.

Description

SALVE FORMULATION
Technical Field
THIS INVENTION relates to a formulation, its preparation and use in the treatment of various skin and other disorders suffered by human and animal species. In particular, it is directed to a salve formulation which can be effective in the treatment of a number of medical ailments, including cancer, abrasions, burns, psoriasis, eczema and other skin disorders.
Background Art
Throughout this specification, unless the contrary is expressly stated, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was, at the priority date, publicly available, known to the public, part of the common general knowledge, or known to be relevant to an attempt to solve any problem with which this specification is concerned.
Modern medicine - treating human and animal ailments with pharmaceuticals - has been effective in managing a wide range of illnesses for many individuals. However, many such pharmaceuticals, usually manufactured in a laboratory from synthetic chemicals, exhibit a long list of possible adverse side effects. As individuals become increasingly more aware of these possible adverse effects, there is mounting interest in the use of natural alternatives to treating an ailment. One particular ailment that attracts significant research, both from the pharmaceutical and natural health industries, is cancer. Cancer is the abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, metastasize (spread). Cancer is not one disease. It is a group of more than 100 different and distinctive diseases. Cancer can involve any tissue of the body and have many different forms in each body area. A prevalent form of cancer in sunny climates is skin cancer - the abnormal growth of skin cells - which most often develops on skin exposed to the sun. However, this form of cancer can also occur on areas of skin not ordinarily exposed to sunlight. There are three major types of skin cancer - basal cell carcinoma, squamous cell carcinoma and melanoma. Herbal medicines in particular have found favour in the treatment of all forms of cancer and there are a number of formulations which assist in the arresting of cancer. Some of these formulations are taken internally, others as singular formulations applied topically. Disadvantages of an internally-taken formulation range include unpleasant taste to the individual and the difficulty for some individuals to readily swallow medications, particularly if they are in a solid tablet-like form. A topical formulation often includes significant quantities of oil-based ingredients which may not readily absorb into the skin leaving the user of the formulation with an uncomfortable "greasy feeling" on the skin orwhich, if in excessive concentration, may even lead to the body sensing that the skin is becoming dehydrated and consequently producing an additional oily secretion from the sebaceous glands (sebum) to insulate the skin from the perceived further loss of moisture - thereby exacerbating the "greasy feeling."
It is thus a general object of the present invention to overcome, or at least ameliorate, one or more of the above-mentioned disadvantages.
Summary of the Invention
As a first aspect of the present invention, there is provided a formulation for the effective topical treatment of one or more skin ailments selected from the group comprising basal cell carcinoma, squamous cell carcinoma, melanoma, abrasions, burns, psoriasis, eczema and other skin disorders, said formulation including the elements:
Backhousia citriodora leaf;
Pittosporum angustifolium leaf;
an extractant; and
a viscosity modifier.
Preferably, said extractant includes a triglyceride radical.
More preferably, said extractant is a triglyceride-containing oil.
Most preferably, said triglyceride-containing oil is a non-volatile natural oil.
In an embodiment of the present invention, said non-volatile natural oil is obtained from Helianthus annuus. (sunflower oil)
Preferably, said viscosity modifier is a wax.
Preferably, said wax is of a plant or animal origin.
More preferably, said wax is of animal origin.
In an embodiment of the present invention, said wax of animal origin is cera alba. (bees wax)
Preferably, said elements are present in the following percentages by weight:
approximately 5% to 10% of said Backhousia citriodora leaf;
approximately 5% to 10% of said Pittosporum angustifolium leaf;
approximately 70% to 80% of said extractant; and
approximately 5% to 15% of said viscosity modifier.
More preferably, said elements are present in the following percentages by weight:
approximately 10% of said Backhousia citriodora leaf;
approximately 10% of said Pittosporum angustifolium leaf;
approximately 70% of said extractant; and
approximately 10% of said viscosity modifier.
Optionally, the formulation of the present invention can include an additional carrier, diluent or adjuvant.
As used throughout the specification, the term "carrier or diluent" denotes an organic or inorganic, natural or synthetic material with which the formulation of the present invention is combined in order to facilitate the application of that formulation to the area to be treated. This carrier or diluent is generally inert. Similarly, the term "adjuvant" has the usual meaning in the art to describe a material which aids the efficacy of the formulation.
As a second aspect of the present invention, there is provided a process for the preparation of a formulation as hereinbefore described for the effective topical treatment of one or more skin ailments, said process including:
a required quantity of said Pittosporum angustifolium leaf is dried;
after said leaf has dried, said dried leaf is ground to a powder;
a required quantity of said Backhousia citriodora leaf is immersed in sufficient said extractant for a period until said leaf is translucent;
a required quantity of said viscosity modifier is at least partially liquified if necessary by the application of heat;
said quantity of said Backhousia citriodora leaf in said extractant is added to said viscosity modifierand substantially evenly distributed therethrough toform an emulsion;
said powder of said dried Pittosporum angustifolium leaf is added to said emulsion, evenly distributed therethrough and filtered, the resultant filtrate comprising said formulation.
A third aspect of the present invention is the provision of a method for the effective treatment of one or more skin ailments selected from the group comprising basal cell carcinoma, squamous cell carcinoma, melanoma, abrasions, burns, psoriasis, eczema and other skin disorders to a being requiring said treatment comprising the topical application of a said formulation as hereinbefore described to an area of said being (animal or human) requiring said treatment.
Detailed Description of a Preferred Embodiment of the Formulation and its Uses
Formulation
Pittosporum angustifolium leaf (200g) is placed in a dark environment for approximately four (4) weeks until dried. Once dried, the leaf is ground to a fine powder. Backhousia citriodora leaf (250g) is immersed in sunflower oil (1840g) and placed in a dark environment for approximately six (6) weeks until the leaf is translucent. Bees wax (290g) is heated until partially liquified. The mixture of Backhousia citriodora leaf and sunflower oil is added to the heated bees wax and stirred to evenly combine to form an emulsion. Once the emulsion has formed, the dried Pittosporum angustifolium leaf is added and stirred to evenly distribute therethrough. The resultant mixture is filtered and the resultant filtrate (the required formulation) isolated and placed into a suitable storage vessel until required for use.
The use of sunflower oil, which extracts the active ingredients from the Backhousia citriodora leaf, also has the additional benefits of acting as a carrier oil for those extracted active ingredients and as an emollient. Similarly, the use of bees wax to reach the required viscosity of the formulation has the additional benefits of its anti microbial and emollient properties.
Example 1
FIG. 1 is an illustration of damage to a human elbow following surgery but prior to the application of the formulation of the present invention. After twice daily topical application of the above-exemplified formulation for five (5) weeks, there was very little internal or external scarring of the skin of the elbow.
Example 2
FIG. 2 is an illustration of the repair of damage to a human right hand following reconstructive surgery after the daily topical application of the above-exemplified formulation for three (3) weeks. There was very little external scarring of the skin.
Example 3
Daily topical use of the above-exemplified formulation significantly reduced bed sores when compared to allopathic pharmaceuticals.
Example 4
Twice daily topical application of the above-exemplified formulation to mosquito bites significantly reduced the itching from such bites and healed any existing mosquito-bite sores within a few days when compared to allopathic pharmaceuticals.
Example 5
Topical application of the above-exemplified formulation repaired long-standing skin scaring of several years.
Example 6
Topical application of the above-exemplified formulation eliminated long-standing fungal infection on toe nails.
Example 7
FIG. 3 is an illustration of cancerous skin growths (sun damage) to the crown and forehead of an adult male. The male suffered significant pain and discomfort upon treatment with the allopathic cytotoxic chemotherapeutic antimetabolite Efudex (Fluorouracil). The treatment was terminated and the above-exemplified formulation was applied thrice daily for approximately 5 weeks. No pain or discomfort was exhibited. FIG. 4 illustrates the significant improvement after the approximately 5 weeks.
Example 8
FIG. 5 is an illustration of the damage to a leg immediately after removal of stitches following a surgical operation. FIG. 6 illustrates the improvement to the area after 6 weeks application of the above-exemplified formulation.
The present invention thus offers a number of advantages which include:
it is a topical application and therefore avoids the unpleasant taste and/or the possible difficulty to readily swallow for an individual when internally-taking allopathic medications; and
comprises only natural products devoid of any artificial additives, thereby reducing the possibility of adverse side effects.
The terms "comprising" or "comprises" as used throughout the specification and claims are taken to specify the presence of the stated features, integers and components referred to but not preclude the presence or addition of one or more other feature/s, integer/s, component/s or group thereof.
It will be appreciated that the above described embodiment is only an exemplification of the various aspects of the present invention and that modifications and alterations can be made thereto without departing from the inventive concept as defined in the following claims.

Claims (15)

1. A formulation for the effective topical treatment of one or more skin ailments selected from the group comprising basal cell carcinoma, squamous cell carcinoma, melanoma, abrasions, burns, psoriasis, eczema and other skin disorders, said formulation including the elements:
Backhousia citriodora leaf;
Pittosporum angustifolium leaf;
an extractant; and
a viscosity modifier.
2. A formulation as defined in Claim 1 wherein said extractant includes a triglyceride radical.
3. A formulation as defined in Claim 2 wherein said extractant is a triglyceride containing oil.
4. A formulation as defined in Claim 3 wherein said triglyceride-containing oil is a non-volatile natural oil.
5. A formulation as defined in Claim 4 wherein said non-volatile natural oil is obtained from Helianthus annuus.
6. A formulation as defined in any one of Claims 1 to 5 wherein said viscosity modifier is a wax.
7. A formulation as defined in Claim 6 wherein said wax is of a plant or animal origin.
8. A formulation as defined in Claim 7 wherein said wax is of animal origin.
9. A formulation as defined in Claim 8 wherein said wax of animal origin is cera alba.
10. A formulation as defined in any one of Claims 1 to 9 wherein said elements are present in the following percentages by weight:
approximately 5% to 10% of said Backhousia citriodora leaf;
approximately 5% to 10% of said Pittosporum angustifolium leaf;
approximately 70% to 80% of said extractant; and
approximately 5% to 15% of said viscosity modifier.
11. A formulation as defined in any one of Claims 1 to 9 wherein said elements are present in the following percentages by weight:
approximately 10% of said Backhousia citriodora leaf;
approximately 10% of said Pittosporum angustifolium leaf;
approximately 70% of said extractant; and
approximately 10% of said viscosity modifier.
12. A formulation as defined in any one of Claims 1 to 11 which further includes an additional carrier, diluent or adjuvant.
13. A process for the preparation of a formulation as defined in any one of Claims 1 to 12, said process including:
a required quantity of said Pittosporum angustifolium leaf is dried;
after said leaf has dried, said dried leaf is ground to a powder;
a required quantity of said Backhousia citriodora leaf is immersed in sufficient said extractant for a period until said leaf is translucent;
a required quantity of said viscosity modifier is at least partially liquified if necessary by the application of heat;
said quantity of said Backhousia citriodora leaf in said extractant is added to said viscosity modifier and substantially evenly distributed therethrough to form an emulsion;
said powder of said dried Pittosporum angustifolium leaf is added to said emulsion, evenly distributed therethrough and filtered, the resultant filtrate comprising said formulation.
14. A method for the effective topical treatment of one or more skin ailments selected from the group comprising basal cell carcinoma, squamous cell carcinoma, melanoma, abrasions, burns, psoriasis, eczema and other skin disorders to a being requiring said treatment comprising the topical application of a said formulation as defined in any one of Claims 1 to 12 to an area of said being requiring said treatment.
15. A method as defined in Claim 14 wherein said being is a human being.
AU2019204432A 2019-06-24 2019-06-24 Salve formulation Abandoned AU2019204432A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019204432A AU2019204432A1 (en) 2019-06-24 2019-06-24 Salve formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2019204432A AU2019204432A1 (en) 2019-06-24 2019-06-24 Salve formulation

Publications (1)

Publication Number Publication Date
AU2019204432A1 true AU2019204432A1 (en) 2021-01-14

Family

ID=74103410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019204432A Abandoned AU2019204432A1 (en) 2019-06-24 2019-06-24 Salve formulation

Country Status (1)

Country Link
AU (1) AU2019204432A1 (en)

Similar Documents

Publication Publication Date Title
JPH07505133A (en) A skin treatment mixture containing Aloe Vera extract that has been chilled and has its yellow sap and aloin removed.
WO2008140200A1 (en) External compositions for the skin
DE3784695T2 (en) Use of Gramineae extracts as a medicine.
CN101524321A (en) Traditional Chinese medicine anti-allergic skin-wetting lipstick and preparation method thereof
US20200330543A1 (en) A topical herbal healing formulation
CN104784223A (en) Composition with itching removing function and preparation method thereof
Dickinson et al. Rolling Stone
DE69730214T2 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX
DE2448648C3 (en) Preparation for the treatment of gastritis, gastric and duodenal ulcers
AU2019204432A1 (en) Salve formulation
WO2016152519A1 (en) External medicine for diffuse plexiform neurofibroma
CN107049881A (en) A kind of dog cat health fragrance involves its preparation method
Prakash et al. Medicoethnozoological studies on anamniotes fauna of Devipatan division of Uttar Pradesh, India
JPH10120579A (en) Skin preparation for improving sputum for external use
KR20160043430A (en) Composition for preventing hair loss, promoting hair generation, or enhancing moist and glossy of hair and manufacturing method thereof
KR100593707B1 (en) Cosmetic Products and their manufacturing methods helping to improve acnegenic and seborrheic skin through anti-microbial action and inhibitory action of sebum secretion.
CN108619486B (en) Ointment for treating skin diseases and preparation method thereof
US20140127315A1 (en) Caudal Salve
KR101326679B1 (en) Skin external composition for treating or alleviating diaper rash containing zinc oxide stabilized by polyglyceryl-2 dipolyhydroxystearate
EP3013423B1 (en) Composition comprising oleum coctus urticae
KR102369744B1 (en) Anti-inflammatory composition comprising buddleja davidii extract
AU2017239512A1 (en) Skin care preparation and method of use
KR102113431B1 (en) Anti-inflammatory composition containing medicinal herbs
JPH10120561A (en) Skin preparation for improving sputum for external use
CN107714834A (en) A kind of composition of camellia oil preparation for external use, preparation method and applications

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period